- Home
- NXP vs NRIX Comparison
NXP vs NRIX Comparison
Compare NXP & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- NRIX
- Stock Information
- Founded
- NXP 1992
- NRIX 2009
- Country
- NXP United States
- NRIX United States
- Employees
- NXP N/A
- NRIX N/A
- Industry
- NXP Trusts Except Educational Religious and Charitable
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- NXP Finance
- NRIX Health Care
- Exchange
- NXP Nasdaq
- NRIX Nasdaq
- Market Cap
- NXP 744.2M
- NRIX 750.4M
- IPO Year
- NXP N/A
- NRIX 2020
- Fundamental
- Price
- NXP $14.32
- NRIX $16.75
- Analyst Decision
- NXP
- NRIX Strong Buy
- Analyst Count
- NXP 0
- NRIX 14
- Target Price
- NXP N/A
- NRIX $26.50
- AVG Volume (30 Days)
- NXP 70.0K
- NRIX 1.7M
- Earning Date
- NXP 01-01-0001
- NRIX 10-09-2025
- Dividend Yield
- NXP 4.04%
- NRIX N/A
- EPS Growth
- NXP N/A
- NRIX N/A
- EPS
- NXP 0.54
- NRIX N/A
- Revenue
- NXP N/A
- NRIX $83,687,000.00
- Revenue This Year
- NXP N/A
- NRIX $58.48
- Revenue Next Year
- NXP N/A
- NRIX N/A
- P/E Ratio
- NXP $26.81
- NRIX N/A
- Revenue Growth
- NXP N/A
- NRIX 48.32
- 52 Week Low
- NXP $12.91
- NRIX $8.18
- 52 Week High
- NXP $14.89
- NRIX $23.00
- Technical
- Relative Strength Index (RSI)
- NXP 44.41
- NRIX 78.50
- Support Level
- NXP $14.20
- NRIX $12.43
- Resistance Level
- NXP $14.49
- NRIX $17.65
- Average True Range (ATR)
- NXP 0.18
- NRIX 1.00
- MACD
- NXP -0.01
- NRIX 0.42
- Stochastic Oscillator
- NXP 33.34
- NRIX 88.13
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.